MedTrace Logo

I-125 Versus Pd-103 for Medium Risk Prostate Cancer

NCT00486499 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 660

Last updated 2007-06-14

No results posted yet for this study

Summary

hypothesis: the shorter half-life of Pd-103 versus I-125, will increase the rate of tumor eradication.

A total of 660 patients with AJC clinical stage T1c-T2a prostatic carcinoma (Gleason grade 7 to 9 and/or PSA 10-20 ng/ml) will be randomized to implantation with I-125 (144 Gy) versus Pd-103 (124 Gy).

Conditions

Interventions

PROCEDURE

I-125 versus Pd-103 radioactive seed insertion

Sponsors & Collaborators

  • Dr. Gregory Merrick

    collaborator UNKNOWN

  • Theragenics Corporation

    collaborator INDUSTRY

  • VA Puget Sound Health Care System

    lead FED

Principal Investigators

  • Kent E Wallner, MD · VA Puget Sound, Group Health Cooperative, U of Washington

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00486499 on ClinicalTrials.gov